IOL 2014.05.12 15:37
US drugmaker Pfizer.
London - US drugmaker Pfizer pressed the scientific case for its
controversial plan to acquire AstraZeneca on Monday as its chief executive
prepared for a grilling from British lawmakers.
In the latest phase of Pfizer's campaign to counter critics of its proposed
$106 billion deal, research head Mikael Dolsten said he had been through
five different mergers and acquisitions and denied such big transactions
PASCAL, PFIZER, MERGER, CURIOSITY, TAKEOVER, SCIENTIST, Read, Cameron, Willetts, USA, United Kingdom